Provided by Tiger Trade Technology Pte. Ltd.

CervoMed

3.99
-0.0500-1.24%
Post-market: 4.200.2075+5.20%19:56 EDT
Volume:18.15K
Turnover:72.82K
Market Cap:36.92M
PE:-1.34
High:4.19
Open:4.04
Low:3.97
Close:4.04
52wk High:13.13
52wk Low:3.51
Shares:9.25M
Float Shares:4.93M
Volume Ratio:0.61
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9824
EPS(LYR):-2.9824
ROE:-93.92%
ROA:-53.62%
PB:2.03
PE(LYR):-1.34

Loading ...

Roth MKM Remains a Buy on CervoMed (CRVO)

TIPRANKS
·
Apr 15

CervoMed Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 08

CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia

TIPRANKS
·
Apr 08

CervoMed says new Phase 2b MRI analysis supports neflamapimod slowing DLB progression

Reuters
·
Apr 07

CervoMed (CRVO) Gets a Buy from JonesTrading

TIPRANKS
·
Apr 07

CervoMed Posts Investor Presentation Under Regulation FD Disclosure

TIPRANKS
·
Mar 24

Cervomed Inc. Publishes Presentation Factsheet

Reuters
·
Mar 24

CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results

TIPRANKS
·
Mar 20

CervoMed Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 20

BUZZ-U.S. STOCKS ON THE MOVE-Rivian,  Biohaven, CervoMed

Reuters
·
Mar 19

CervoMed’s neflamapimod shows efficacy in dementia with DLB

TIPRANKS
·
Mar 19

BRIEF-CervoMed Announces New Data At The Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’S Positive Effects In Dementia With Lewy Bodies (DLB) In Patients Without Alzheimer’S Disease Co-Pathology

Reuters
·
Mar 19

CervoMed reports Phase 2b neflamapimod benefit in DLB patients with plasma pTau181 below 21 pg/mL

Reuters
·
Mar 19

CervoMed Announces New Data at the Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’s Positive Effects in Dementia With Lewy Bodies (Dlb) in Patients Without Alzheimer’s Disease Co-Pathology

THOMSON REUTERS
·
Mar 19

CervoMed Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 18

Chardan Raises Price Target on CervoMed to $21 From $15, Keeps Buy Rating

MT Newswires Live
·
Mar 18

CervoMed price target lowered to $11 from $19 at Roth Capital

TIPRANKS
·
Mar 18

Chardan Capital Sticks to Their Buy Rating for CervoMed (CRVO)

TIPRANKS
·
Mar 18

CervoMed price target raised to $21 from $15 at Chardan

TIPRANKS
·
Mar 18

CervoMed Reports 2025 Results, Advances Neflamapimod Programs

TIPRANKS
·
Mar 18